About 1 result found for searched term "Navicixizumab" (0.135 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M24764 | Navicixizumab | Notch |
| OMP-305B83 Anti-DLL4 Reference Antibody | ||
| Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
